Got investment from #Johnson & Johnson Innovation, #TempoTherapeutics leverages #MAP scaffold materials to tap into the regenerative market!
On March 19th, 2024, Tempo Therapeutics successfully secured a total of $12 million in Series A financing. This round of financing was co-led by the renowned investment institution #Galaxy-Sirius Partners and the healthcare giant Johnson & Johnson Innovation (#JJI).
Tempo Therapeutics is a innovative biomaterial company, focus on explore a series of new synthetic biomaterial with advanced MAP technology platform. These materials show significant potential in surgical reconstruction and regenerative medicine, steadily changing medical technology.
So far, the company has constructed five production channels, covers 11 application scenarios ranging from complex surgical wound repair to medical aesthetics, cartilage regeneration, and even vaccine development. Tempo Therapeutics' associated product pipeline, TT101-Biosurgery, is the fastest developing and has already entered the clinical trial phase. TT101-Biosurgery is especially designed for solving the challenges of tissue healing after complex surgical wounds and the implantation of medical. Cell migration is a key step in wound healing and tissue regeneration, yet traditional healing agents often have limited effects due to their hindrance of cell migration. TT101-Biosurgery, through its innovative microporous gel system, optimizes the tissue-device interface, providing an ideal environment for cell migration and tissue regeneration.
As the sole developer of tissue scaffolds based on MAP technology, Tempo Therapeutics is preparing to reach key developmental milestones by establishing the safety and efficacy of its two main products: #TT101-Biosurgery: Complex Surgical Wound, for complex surgical sites that expose bone, tendon, or fascia; TT101-Biosurgery: Abdominal, for reinforcement of fascial incisions.
🌍👍🇩🇪